Robert R Henry

List of Publications by Year
in descending order

50 papers	6,118 citations	117453 34 h-index	189595 50 g-index
55 all docs	55 docs citations	55 times ranked	8303 citing authors

#	Article	IF	Citations
1	p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes. JCI Insight, 2022, 7, .	2.3	3
2	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes Care, 2019, 42, 2108-2116.	4.3	50
3	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodiumâ€“Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42, 1147-1154.	4.3	249
4	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 812-821.	2.2	117
5	Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. Diabetes, Obesity and Metabolism, 2018, 20, 1632-1641.	2.2	15
6	Alirocumab vs usual lipidâ€lowering care as addâ€on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DMâ€DYSLIPIDEMIA randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1479-1489.	2.2	76
7	Effect of a glucagon receptor antibody (REMDâ€477) in type 1 diabetes: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 1302-1305.	2.2	50
8	Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study. Diabetes Care, 2018, 41, 613-619.	4.3	25
9	Treatment satisfaction with ITCA 650, a novel drugâ€device delivering continuous exenatide, versus twiceâ€daily injections of exenatide in type 2 diabetics using metformin. Diabetes, Obesity and Metabolism, 2018, 20, 638-645.	2.2	6
10	Circulating ApoJ is closely associated with insulin resistance in human subjects. Metabolism: Clinical and Experimental, 2018, 78, 155-166.	1.5	24
11	Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Technology and Therapeutics, 2018, 20, 715-724.	2.4	49
12	SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia, 2018, 61, 2126-2133.	2.9	68
13	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes Care, 2018, 41, 1792-1800.	4.3	25
14	Dapagliflozin in patients with type 1 diabetes: <scp>A</scp>post hoc analysis of the effect of insulin dose adjustments on 24â€hour continuously monitored mean glucose and fasting Î²â€hydroxybutyrate levels in a phase <scp>IIa</scp> pilot study. Diabetes, Obesity and Metabolism, 2017, 19, 814-821.	2.2	34
15	Deletion of interleukin 1 receptor-associated kinase 1 (Irak1) improves glucose tolerance primarily by increasing insulin sensitivity in skeletal muscle. Journal of Biological Chemistry, 2017, 292, 12339-12350.	1.6	28
16	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. New England Journal of Medicine, 2017, 377, 2337-2348.	13.9	322
17	Efficacy and safety of alirocumab in insulinâ€treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DMâ€INSULIN</scp> randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1781-1792.	2.2	105
18	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular Diabetology, 2017, 16, 70.	2.7	25

#	Article	IF	Citations
19	Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Preference and Adherence, 2016, Volume 10, 1299-1307.	0.8	448
20	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. Endocrine Practice, 2016, 22, 753-762.	1.1	242
21	Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. Age, 2016, 38, 485-493.	3.0	10
22	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. European Heart Journal, 2016, 37, 2981-2989.	1.0	142
23	Diabetic Ketoacidosis With Canagliflozin, a Sodiumâ€“Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. Diabetes Care, 2016, 39, 532-538.	4.3	83
24	Type 2 diabetes mellitus. Nature Reviews Disease Primers, 2015, 1, 15019.	18.1	1,308
25	American Association of Clinical Endocrinologists and American College of Endocrinology â€“ Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan â€“ 2015 â€” Executive Summary. Endocrine Practice, 2015, 21, 413-437.	1.1	359
26	Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes. Diabetes Care, 2015, 38, 1189-1196.	4.3	41
27	Efficacy and Safety of Canagliflozin, a Sodiumâ€“Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care, 2015, 38, 2258-2265.	4.3	235
28	Sodiumâ€“Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport. Diabetes Care, 2015, 38, 2344-2353.	4.3	186
29	Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Diabetes Care, 2015, 38, 412-419.	4.3	191
30	Can a Selective PPARÎ³ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?. Diabetes Care, 2014, 37, 1918-1923.	4.3	61
31	Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2014, 311, 1515.	3.8	206
32	Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. Journal of Diabetes and Its Complications, 2014, 28, 393-398.	1.2	71
33	Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier. Molecular Cell, 2014, 56, 425-435.	4.5	243
34	Evaluation of the dual peroxisome proliferatorâ€“activated receptor Î±/Î³ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial. American Heart Journal, 2013, 166, 429-434.e1.	1.2	39
35	(â^')-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients. International Journal of Cardiology, 2013, 168, 3982-3990.	0.8	83
36	A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetesâ˜†â˜†This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.. Clinical Therapeutics, 2013, 35, 634-645.e1.	1.1	26

#	Article	IF	Citations
37	Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. Diabetes Care, 2013, 36, 2559-2565.	4.3	43
38	PPAR Î³ Agonists and the Future for Insulin Sensitizers. British Journal of Diabetes and Vascular Disease, 2012, 12, 206-210.	0.6	6
39	Effects of epicatechin rich cocoa on REDUX status in human skeletal muscle. FASEB Journal, 2012, 26, 888.11.	0.2	2
40	Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program. Endocrine Practice, 2011, 17, 906-913.	1.1	44
41	Effect of the dual peroxisome proliferator-activated receptor-Î±/Î³ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet, The, 2009, 374, 126-135.	6.3	196
42	Effect of acute exercise on citrate synthase activity in untrained and trained human skeletal muscle. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 280, R441-R447.	0.9	134
43	Early Alteration in Glomerular Reserve in Humans at Genetic Risk of Essential Hypertension. Hypertension, 2001, 37, 898-906.	1.3	23
44	Impaired Muscle Glycogen Synthase in Type 2 Diabetes Is Associated with Diminished Phosphatidylinositol 3-Kinase Activation. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4307-4314.	1.8	56
45	Glucosamine Regulation of Glucose Metabolism in Cultured Human Skeletal Muscle Cells: Divergent Effects on Glucose Transport/Phosphorylation and Glycogen Synthase in Non-Diabetic and Type 2 Diabetic Subjects1. Endocrinology, 1999, 140, 3971-3980.	1.4	51
46	Troglitazone Effects on Gene Expression in Human Skeletal Muscle of Type II Diabetes Involve Up-Regulation of Peroxisome Proliferator-Activated Receptor-Î³1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2830-2835.	1.8	89
47	Effects of Tumor Necrosis Factor-Î± on Glucose Metabolism in Cultured Human Muscle Cells from Nondiabetic and Type 2 Diabetic Subjects1. Endocrinology, 1998, 139, 4793-4800.	1.4	44
48	Strategies for preventing type II diabetes. Postgraduate Medicine, 1997, 101, 181-189.	0.9	5
49	Benefits and Limitations of Very-Low-Calorie Diet Therapy in Obese NIDDM. Diabetes Care, 1991, 14, 802-823.	4.3	125
50	Reduced Glucose-Induced Thermogenesis Is Present in Noninsulin-Dependent Diabetes Mellitus without Obesity*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 801-807.	1.8	16